Clinical characteristics of relapsed bladder cancer patients after curative therapy
| Variables | Total (n=91) | Pair-matched (n=60) | ||||
| Chemoradiation therapy (n=48) | Surgical therapy (n=43) | P value | Chemoradiation therapy (n=30) | Surgical therapy (n=30) | P value | |
| Gender (%) | ||||||
| Male | 41 (85.4) | 33 (76.7) | 0.29 | 23 (76.7) | 22 (73.3) | 0.77 |
| Female | 7 (14.6) | 10 (23.3) | 7 (23.3) | 8 (26.7) | ||
| Age (median (IQR)) | 71 (62–76) | 74 (66–79) | 0.23 | 70 (60–78) | 72 (59–78) | 0.74 |
| ECOG-PS at pembrolizumab (%) | ||||||
| 0–1 | 41 (85.4) | 40 (97.7) | 0.24 | 27 (90.0) | 28 (93.3) | 0.64 |
| >2 | 7 (14.6) | 3 (2.3) | 3 (10.0) | 2 (6.7) | ||
| Smoking history (%) | ||||||
| Never | 17 (35.4) | 13 (30.2) | 0.6 | 11 (36.7) | 7 (23.3) | 0.26 |
| Former/current | 31 (64.6) | 30 (69.8) | 19 (63.3) | 23 (76.7) | ||
| Body mass index (%) | ||||||
| ≥25 | 8 (16.7) | 4 (9.3) | 0.3 | 3 (10.0) | 4 (13.3) | 0.69 |
| <25 | 40 (83.3) | 39 (90.7) | 27 (90.0) | 26 (86.7) | ||
| Pelvic lymph node metastasis at curative therapy (%) | ||||||
| Yes | 16 (33.3) | 7 (16.3) | 0.06 | 10 (33.3) | 7 (23.3) | 0.39 |
| No | 32 (66.4) | 36 (83.7) | 20 (66.7) | 23 (76.7) | ||
| Liver metastasis at pembrolizumab therapy (%) | ||||||
| Yes | 7 (17.1) | 3 (2.3) | 0.25 | 2 (6.7) | 3 (10.0) | 0.64 |
| No | 41 (82.9) | 40 (97.7) | 28 (93.3) | 27 (90.0) | ||
| Visceral metastasis at pembrolizumab therapy (%) | ||||||
| Yes | 35 (72.9) | 18 (41.9) | 0.003* | 20 (66.7) | 15 (50.0) | 0.19 |
| No | 13 (27.1) | 25 (58.1) | 10 (33.3) | 15 (50.0) | ||
| Hemoglobin concentration at pembrolizumab therapy (%) | ||||||
| >100 g/L | 22 (45.8) | 33 (76.7) | 0.003* | 17 (56.7) | 22 (73.3) | 0.18 |
| ≤100 g/L | 26 (54.2) | 10 (23.3) | 13 (43.3) | 8 (26.7) | ||
| NLR at pembrolizumab therapy (%) (median (IQR)) | 4.80 (3.50–7.84) | 3.67 (2.36–5.5) | 0.01* | 4.05 (2.85–6.12) | 3.6 (2.34–6.33) | 0.42 |
| Previous chemotherapy cycles (median (IQR)) | 3 (1–4) | 3 (2–6) | 0.009* | 3 (2.5–4) | 3 (2–4) | 0.91 |
| Time to pembrolizumab therapy from curative therapy (months) (median (IQR)) | 16.5 (7.58–32.5) | 11.9 (6.33–28.3) | 0.29 | 19.9 (8.28–37.2) | 11.2 (5.69–29.0) | 0.18 |
*p<0.05
ECOG-PS, Eastern Cooperative Oncology Group Performance Status; NLR, neutrophil-to-lymphocyte ratio.